Research Overview
Pharmaceutical Mergers and Acquisitions Create Need for Open Standards in LIMS Design
The increasing trend towards mergers and acquisitions in the pharmaceuticals industry in Europe
has had a direct impact on the laboratory information management systems (LIMS) market as it brings
together multiple solutions of different vendors. The acquiring company then faces the difficult
task of establishing effective communication between the various systems so that there are minimal
technical incompatibilities and product uncertainties. The challenge for LIMS vendors, therefore, is
to develop an open, standardised technology platform to ease end users difficulties in
understanding the technicalities of the solution design or minimising training costs. The impact of
this challenge will decrease as LIMS vendors introduce a higher degree of configurability in the
implementation design.
This Frost & Sullivan research service presents a comprehensive analysis of LIMS
implementations and their potential applications in pharmaceuticals research and development as well
as manufacturing. The analysis includes primary growth factors, challenges as well as restraints
along with detailed revenue forecasts and major opportunities within the market.
Deluge of Data Encourages Scientific Data Management through LIMS
Following the completion of the Human Genome Project, there has been a tremendous surge in
biological variable data and pharmaceutical companies are under pressure to research as many as 100
compounds a week. Faced with the challenge of organising this huge volume of data and improving
quality control, companies are looking for an integrated platform such as LIMS that effectively
combines laboratory research with complex discovery and informatics.
"LIMS has been instrumental in reducing companies time-to-market and streamlining the
drug manufacturing process by minimising batch-to-batch rejects and false positives to derive faster
and more accurate results," remarks the analyst of this research service. "From a purely
sample-centric viewpoint in the past, LIMS has progressed to managing data flow across the
enterprise in an optimal manner." With technology developments underway to enhance flexibility
and configurability in LIMS solutions, companies can aim to achieve product differentiation by
integrating them with researchers and analysing genotype and phenotype variables on the same
platform.
Opportunities Abound for Vendors with Strong Product Differentiation
There is no dearth of opportunities for vendors in the technology-driven LIMS market, which is
characterised by quick innovation cycles. However, intensifying competition and the strict
regulatory climate in the pharmaceuticals industry pose a strong challenge. Vendors that are able to
bring out product differentiation to meet the changing laboratory experimental requirements are most
likely to succeed.
"Given the high entry costs to the pharmaceutical industry and stringent regulatory
measures, LIMS vendors can emerge successful if they develop a product differentiating factor that
has the ability to integrate with the laboratory environment and harmonise with the business
processes," says the analyst. Companies are already taking steps to make their solutions more
interactive and customer-friendly. This is likely to enhance sample traceability, instrument
interfacing and final report generation in a formatted manner.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new theories tested in
hundreds of companies across many industries, Frost & Sullivan has evolved its Growth
Partnership Services (GPS) programme that provides established and emerging firms with powerful
growth visions. Moving beyond token mission statements, GPS provides an actionable vision to growth
consulting partners by illustrating how key intelligence and strategic research based on defined
goals can guide day-to-day behaviour and overall company direction. The foundation of Frost &
Sullivans GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common mistakes resulting
from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximise the potential for growth within a firms internal and external environment, Frost
& Sullivan consultants can facilitate the creation of strategic programmes that deliver improved
market success. Frost & Sullivans strengths lie in combining strategic understanding with
market expertise and applying these with absolute commitment to its clients growth.
Benefits of this Service
- Focuses on the growth opportunities for LIMS and their potential in the pharmaceuticals industry
- Analyses the competitive structure and discusses strategic recommendations for technical and
business challenges confronting the adoption rate for these applications
- Provides valuable end-user feedback that can help companies move up the value chain on their
product offerings
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this
research service:
- Pharmaceutical research and development (R&D)
- Pharmaceutical manufacturing
Technologies
The following technology is covered in this research service:
- Laboratory Information Management Systems (LIMS): These are information management systems
powered by IT in a non-hospital environment. LIMS serves as a centralised knowledge repository and
thus eliminates paper records. It organises biological data collection and retrieval, thereby
helping researchers improve throughput in their experiments and facilitate resource planning in the
organisation.
Whats Included
- Key market trends
- Market revenues by segment
- Technology trends
- Competition structure
- End-user structure
- Strategic recommendations
View Cart
